



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimballa
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Patrick E. Garrett

Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Mark Fox Evens
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang
Christopher J. Walsh

W. Blake Coblentz
James J. Pohl*
John T. Haran
Mark W. Rygiel
Kevin W. McCabe
Michael R. Malek*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

December 21, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8525

INTERNET ADDRESS:
BRIAND@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1615

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Appl. No. 10/550,518; § 371 Date: September 23, 2005
(U.S. Nat'l Phase of Int'l Appl. No. PCT/EP2004/003165; I.A. Date: March 25, 2004)
For: **Packaging of Immunostimulatory Oligonucleotides Into Virus-Like
Particles: Method of Preparation and Use**
Inventors: Martin F. BACHMANN *et al.*
Our Ref: 1700.0630000/BJD/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. PTO-1449 (9 pages) citing seventy-two (72) documents (AA1-AF3 and AL1-AO9);
3. Copy of forty-four (44) cited documents (AL1-AP1; AL2-AP2; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL7-AP7; AL8-AP8; and AL9-AO9);
4. Form PTO/SB/08B (11 pages) citing one hundred and two (102) documents (NPL1-NPL102);
5. Copy of one hundred and two (102) cited documents (NPL1-NPL10; NPL11-NPL20; NPL21-NPL30; NPL31-NPL40; NPL41-NPL50; NPL51-NPL60; NPL61-NPL70; NPL71-NPL80; NPL81-NPL90; NPL91-NPL100; and NPL101-NPL102); and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

Commissioner for Patents
December 21, 2006
Page 2

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "B. Del Buono", with a long horizontal flourish extending to the right.

Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/WBC:cpn
Enclosures

613459_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Martin F. BACHMANN *et al.*

Appl. No.: 10/550,518

(U.S. Nat'l Phase of PCT/EP2004/003165)

§ 371 Date: September 23, 2005

For: **Packaging of Immunostimulatory
Oligonucleotides Into Virus-Like
Particles: Method of Preparation
and Use**

Confirmation No.: 8347

Art Unit: 1615

Examiner: *To Be Assigned*

Atty. Docket: 1700.0630000/BJD/WBC

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO-1449 and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **AL1** to **AO9** and **NPL1** to **NPL102** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **AA1** to **AF3**, cited on the attached IDS Form, PTO-1449, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: Dec. 21, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

599190_1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,722,840	02/02/1988	Valenzuela <i>et al.</i>			09/19/1985
	AB1	4,918,166	08/17/1990	Kingsman <i>et al.</i>			10/26/1987
	AC1	4,959,314	09/25/1990	Mark <i>et al.</i>			02/07/1985
	AD1	5,143,726	09/01/1992	Thornton <i>et al.</i>			11/20/1989
	AE1	5,334,394	08/02/1994	Kossovsky <i>et al.</i>			01/04/1993
	AF1	5,565,548	10/15/1996	Neurath <i>et al.</i>			03/15/1993
	AG1	5,698,424	12/16/1997	Mastico <i>et al.</i>			06/26/1992
	AH1	5,780,448	07/14/1998	Davis			11/04/1996
	AI1	5,844,075	12/01/1998	Kawakami <i>et al.</i>			04/05/1995
	AJ1	5,871,747	02/16/1999	Gengoux-Sedlik <i>et al.</i>			09/13/1993
	AK1	5,874,560	02/23/1999	Kawakami <i>et al.</i>			04/22/1994

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 038 154 B1	10/21/1981	Europe			Yes No
	AM1	EP 0 201 416 A1	11/12/1986	Europe			Yes No
	AN1	EP 0 385 610 B1	09/05/1990	Europe			Yes No
	AO1	EP 0 421 635 A1	04/10/1990	Europe			Yes No
	AP1	WO 92/13081 A1	08/06/1992	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1700.0630000/BJD/WBC	APPLICATION NO. 10/550,518
	FIRST NAMED INVENTOR Bachmann, Martin F.	
	FILING DATE September 23, 2005	ART UNIT 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	5,935,821	08/10/1999	Chatterjee <i>et al.</i>			11/21/1996
	AB2	5,939,598	08/17/1999	Kucherlapati <i>et al.</i>			07/30/1992
	AC2	5,994,523	11/30/1999	Kawakami <i>et al.</i>			01/16/1998
	AD2	6,025,470	02/15/2000	Valmori <i>et al.</i>			06/23/1997
	AE2	6,231,864 B1	05/15/2001	Birkett			02/11/1999
	AF2	6,270,778 B1	08/07/2001	Kawakami <i>et al.</i>			03/12/1999
	AG2	6,277,956 B1	08/21/2001	Valmori <i>et al.</i>			04/16/1998
	AH2	6,326,200 B1	12/04/2001	Valmori <i>et al.</i>			06/18/1998
	AI2	6,368,857 B1	04/09/2002	Valmori <i>et al.</i>			10/05/1999
	AJ2	6,380,364 B1	04/30/2002	Mueller <i>et al.</i>			10/06/1999
	AK2	6,384,190 B1	05/07/2002	Valmori <i>et al.</i>			12/14/1999

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 578 293 A1	01/12/1994	Europe			Yes No
	AM2	WO 94/15585	07/21/1994	WIPO			Yes No
	AN2	EP 0 677 111 B1	10/18/1995	Europe			Yes No
	AO2	WO 95/29193 A2	11/02/1995	WIPO			Yes No
	AP2	WO 96/30523 A2	10/03/1996	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1700.0630000/BJD/WBC	APPLICATION NO. 10/550,518
	FIRST NAMED INVENTOR Bachmann, Martin F.	
	FILING DATE September 23, 2005	ART UNIT 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	6,537,560 B1	03/25/2003	Kawakami <i>et al.</i>			05/05/1998
	AB3	2002/0064533 A1	05/30/2002	Murray			06/04/2001
	AC3	2002/0081295 A1	06/27/2002	Schiller <i>et al.</i>			04/13/2001
	AD3	2003/0050268 A1	03/13/2003	Krieg <i>et al.</i>			03/29/2002
	AE3	2003/0082804 A1	05/01/2003	Valmori <i>et al.</i>			02/21/2001
	AF3	2003/0144482 A1	07/31/2003	Kawakami <i>et al.</i>			07/03/2001
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 98/40100 A1	09/17/1998	WIPO			Yes No
	AM3	WO 98/50071 A1	11/12/1998	WIPO			Yes No
	AN3	WO 98/49195 A1	11/05/1998	WIPO			Yes No
	AO3	WO 98/58751 A1	12/30/1998	WIPO			Yes No
	AP3	WO 99/28478 A1	06/10/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4	WO 99/40934 A1	08/19/1999	WIPO			Yes No
	AM4	WO 99/57289 A2	11/11/1999	WIPO			Yes No
	AN4	WO 00/23955 A1	04/27/2000	WIPO			Yes No
	AO4	WO 00/32227 A2	06/08/2000	WIPO			Yes No
	AP4	WO 00/37610 A2	06/29/2000	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5	WO 00/39304 A2	07/06/2000	WIPO			Yes No
	AM5	WO 00/50461 A1	08/31/2000	WIPO			Yes No
	AN5	WO 00/62800 A2	10/26/2000	WIPO			Yes No
	AO5	WO 01/16320 A1	03/08/2001	WIPO			Yes No
	AP5	WO 01/22972 A2	04/05/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6	WO 01/22990 A2	04/05/2001	WIPO			Yes No
	AM6	WO 01/56603 A1	08/09/2001	WIPO			Yes No
	AN6	WO 01/58478 A1	08/16/2001	WIPO			Yes No
	AO6	WO 01/77158 A1	10/18/2001	WIPO			Yes No
	AP6	WO 01/85208 A2	11/15/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7	WO 01/98333 A2	12/27/2001	WIPO			Yes No
	AM7	WO 02/14478 A2	02/21/2002	WIPO			Yes No
	AN7	WO 02/053141 A2	07/11/2002	WIPO			Yes No
	AO7	WO 02/056905 A2	07/25/2002	WIPO			Yes No
	AP7	WO 02/056907 A2	07/25/2002	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL8	WO 03/024480 A2	03/27/2003	WIPO			Yes No
	AM8	WO 03/024481 A2	03/27/2003	WIPO			Yes No
	AN8	WO 03/031466 A2	04/17/2003	WIPO			Yes No
	AO8	WO 03/039225 A2	05/15/2003	WIPO			Yes No
	AP8	WO 03/040164 A2	05/15/2003	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0630000/BJD/WBCAPPLICATION NO.
10/550,518FIRST NAMED INVENTOR
Bachmann, Martin F.FILING DATE
September 23, 2005ART UNIT
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL9	WO 03/059386 A2	07/24/2003	WIPO			Yes No
	AM9	WO 04/000351 A1	12/31/2003	WIPO			Yes No
	AN9	WO 04/007538 A2	01/22/2004	WIPO			Yes No
	AO9	WO 2004/016282 A1	02/26/2004	WIPO			Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	1	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL1	Adams, S.E., <i>et al.</i> , "The expression of hybrid HIV: Ty virus-like particles in yeast," <i>Nature</i> 329:68-70, Nature Publishing Group (1987)	
	NPL2	Addo, M.M., <i>et al.</i> , "Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but no Correlation to Viral Load," <i>J. Virol.</i> 77:2081-2092, American Society for Microbiology (2003)	
	NPL3	Allen, T.M., <i>et al.</i> , "Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen," <i>J. Immunol.</i> 164:4968-4978, The American Association of Immunologists (2000)	
	NPL4	Altschul, S.F., <i>et al.</i> , "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410, Academic Press Limited (1990)	
	NPL5	Altschul, S.F., <i>et al.</i> , "Issues in searching molecular sequence databases," <i>Nature Genet.</i> 6:119-129, Nature Publishing Group (1994)	
	NPL6	Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Ann. Rev. Immunol.</i> 15:235-270, Annual Reviews Inc. (1997)	
	NPL7	Bachmann, M.F., and Zinkernagel, R., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science Ltd. (1996)	
	NPL8	Bachmann, M.F., <i>et al.</i> , "Induction of protective cytotoxic T cells with viral proteins," <i>Eur. J. Immunol.</i> 24:2228-2236, VCH Verlagsgesellschaft mbH (1994)	
	NPL9	Bachmann, M.F., <i>et al.</i> , "Distinct Roles for LFA-1 and CD28 during Activation of Naive T Cells: Adhesion versus Costimulation," <i>Immunity</i> 7:549-557, Cell Press (1997)	
	NPL10	Bachmann, M.F., <i>et al.</i> , "Four types of Ca ²⁺ -signals in naïve CD8 ⁺ cytotoxic cells after stimulation with T cell agonists, partial agonists and antagonists," <i>Eur. J. Immunol.</i> 27:3414-3419, WILEY-VCH Verlag GmbH (1997)	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

599067_1.DOC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	2	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Bachmann, M.F., <i>et al.</i> , "Functional Maturation of an Anti-viral Cytotoxic T-cell Response," <i>J. Virol.</i> 71:5764-5768, American Society for Microbiology (1997)	
	NPL12	Bachmann, M.F., <i>et al.</i> , "Peptide induced T cell receptor-down regulation on naive T cell predicts agonist/partial agonist properties and strictly correlates with T cell activation," <i>Eur. J. Immunol.</i> 27:2195-2203, WILEY VCH Verlag GmbH (1997)	
	NPL13	Belshe, R.B., <i>et al.</i> , "Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers," <i>J. Inf. Dis.</i> 183:1343-1352, The Infectious Diseases Society of America (2001)	
	NPL14	Berthet-Colominas, C., <i>et al.</i> , "Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab," <i>EMBO J.</i> 18:1124-1136, European Molecular Biology Organization (1999)	
	NPL15	Borisova, G., <i>et al.</i> , "Hybrid Hepatitis B Virus Nucleocapsid Bearing an Immunodominant Region from Hepatitis B Virus Surface Antigen," <i>J. Virol.</i> 67:3696-3701, American Society for Microbiology (1993)	
	NPL16	Brändle, D., <i>et al.</i> , "The shared tumor-specific antigen encoded by mouse gene <i>PIA</i> is a target not only for cytolytic T lymphocytes but also for tumor rejection," <i>Eur. J. Immunol.</i> 28:4010-4019, WILEY VCH Verlag GmbH (1998)	
	NPL17	Brown, W.L., <i>et al.</i> , "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," <i>Intervirology</i> 45:371-380, S. Karger AG (2002)	
	NPL18	Buonaguro, L., <i>et al.</i> , "High efficient production of Pr55 ^(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A," <i>Antiviral Res.</i> 49:35-47, Elsevier Science (2001)	
	NPL19	Chackerian, B., <i>et al.</i> , "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," <i>Proc. Natl. Acad. Sci. USA</i> 96:2373-2378, National Academy of Sciences (1999)	
	NPL20	Clarke, B.E., <i>et al.</i> , "Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria," <i>J. Gen. Virol.</i> 71:1109-1117, SGM (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	3	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	Cohen, P.A., <i>et al.</i> , "CD4 ⁺ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens," <i>Cancer Res.</i> 54:1055-1058, American Association for Cancer Research (1994)	
	NPL22	De Clercq, E., "Interferon Induction by Polynucleotides, Modified Polynucleotides, and Polycarboxylates," <i>Methods Enzymol.</i> 78:227-236, Academic Press, Inc. (1981)	
	NPL23	Desrosiers, R.C., <i>et al.</i> , "Vaccine protection against simian immunodeficiency virus infection," <i>Proc. Natl. Acad. Sci. USA</i> 86:6353-6357, National Academy of Sciences (1989)	
	NPL24	Eckhardt, S.G., <i>et al.</i> , "Hepatitis B Virus Core Antigen Has Two Nuclear Localization Sequences in the Arginine-Rich Carboxyl Terminus," <i>J. Virol.</i> 65:575-582, American Society for Microbiology (1991)	
	NPL25	Engleman, E.G., "Dendritic cells: potential role in cancer therapy," <i>Cytotechnology</i> 25:1-8, Kluwer Academic Publishers (1997)	
	NPL26	Fehr, T., <i>et al.</i> , "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, National Academy of Sciences (1998)	
	NPL27	Fehr, T., <i>et al.</i> , "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J. Exp. Med.</i> 185:1785-1792, The Rockefeller University Press (1997)	
	NPL28	Firat, H., <i>et al.</i> , "H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-3121, WILEY-VCH Verlag GmbH (1999)	
	NPL29	Fitch, J., <i>et al.</i> , "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response," <i>Vaccine</i> 13:1051-1057, Elsevier Science, Ltd. (1995)	
	NPL30	Franken, P., <i>et al.</i> , "HIV-1 Nef protein: Purification, crystallizations, and preliminary X-ray diffraction studies," <i>Protein Sci.</i> 6: 2681-2683, Cold Spring Harbor Laboratory Press (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	4	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	Gerber, S., <i>et al.</i> , "Human Papillomavirus Virus-Like Particles are Efficient Oral Immunogens when Coadministered with <i>Escherichia coli</i> Heat-Labile Enterotoxin Mutant R192G or CpG DNA," <i>J. Virol.</i> 75:4752-4760, American Society for Microbiology (2001)	
	NPL32	Geysen, H.M., <i>et al.</i> , "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002, National Academy of Sciences (1984)	
	NPL33	Gilbert, S.C., <i>et al.</i> , "A protein particle vaccine containing multiple malaria epitopes," <i>Nature Biotechnol.</i> 15:1280-1284, Nature America Publishing (1997)	
	NPL34	Gluckman, J.C., <i>et al.</i> , "In vitro generation of human dendritic cells and cell therapy," <i>Cytokines Cell. Mol. Ther.</i> 3:187-196, Martin Dunitz Ltd. (1997)	
	NPL35	Goldberg, A.L., <i>et al.</i> , "The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides," <i>Mol. Immunol.</i> 39:147-164, Elsevier Science Ltd. (2002)	
	NPL36	Golmohammadi, R., <i>et al.</i> , "The crystal structure of bacteriophage Q β at 3.5 Å resolution," <i>Structure</i> 4:543-554, Current Biology Ltd. (1996)	
	NPL37	Hanke, T., and McMichael, A.J., "Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya," <i>Nature Med.</i> 6:951-955, Nature America Inc. (2000)	
	NPL38	Harding, C.V., and Song, R., "Phagocytic Processing of Exogenous Particulate Antigens by Macrophages for Presentation by Class I MHC Molecules," <i>J. Immunol.</i> 153:4925-4933, The American Association of Immunologists (1994)	
	NPL39	Huston, J.S., <i>et al.</i> , "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods Enzymol.</i> 203:46-88, Academic Press, Inc. (1991)	
	NPL40	Jegerlehner, A., <i>et al.</i> , "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3112, Elsevier Science Ltd. (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	5	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	Jin, X., <i>et al.</i> , "Dramatic Rise in Plasma Viremia after CD8 ⁺ T Cell Depletion in Simian Immunodeficiency Virus-infected Macaques," <i>J. Exp. Med.</i> 189:991-998, The Rockefeller University Press (1999)	
	NPL42	Kaisho, T., and Akira, S., "Toll-like receptors as adjuvant receptors," <i>Biochim. Biophys. Acta</i> 1589:1-13, Elsevier Science (2002)	
	NPL43	Kang, C.Y., <i>et al.</i> , "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles," <i>Biol. Chem.</i> 380:353-364, Walter de Gruyter (1999)	
	NPL44	Klinman, D.M., <i>et al.</i> , "Immunotherapeutic Applications of CpG-Containing Oligodeoxynucleotides," <i>Drug News Perspect.</i> 13:289-296, Prous Science (2000)	
	NPL45	Klovins, J., <i>et al.</i> , "Nucleotide sequence of a ssRNA phage from <i>Acinetobacter</i> : kinship to coliphages," <i>J. Gen. Virol.</i> 83:1523-1533, SGM (2002)	
	NPL46	Kovacovics-Bankowski, M., <i>et al.</i> , "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages," <i>Proc. Natl. Acad. Sci. USA</i> 90:4942-4946, National Academy of Sciences (1993)	
	NPL47	Kozlovskaya, T.M., <i>et al.</i> , "Recombinant RNA phage Q β capsid particles synthesized and self-assembled in <i>Escherichia coli</i> ," <i>Gene</i> 137(1):133-7, Elsevier Science Publishers (1993)	
	NPL48	Kozlovskaya, T. M., <i>et al.</i> , "RNA phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Intervirology</i> 39:9-15, S. Karger AG (1996)	
	NPL49	Kratz, P.A., <i>et al.</i> , "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci. USA</i> 96:1915-1920, National Academy of Sciences (1999)	
	NPL50	Krug, A., <i>et al.</i> , "Identification of CpG oligonucleotide sequences with high induction of IFN- α/β in plasmacytoid dendritic cells," <i>Eur. J. Immunol.</i> 31:2154-2163, WILEY Verlag GmbH (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	6	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL51	Kündig, T.M., <i>et al.</i> , "Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs," <i>Science</i> 268:1343-1347, American Association for the Advancement of Science (1995)	
	NPL52	Kuramoto, E., <i>et al.</i> , "Oligonucleotide Sequences Required for Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131, Japanese Cancer Association (1992)	
	NPL53	Lechner, F., <i>et al.</i> , "Virus-Like Particles as a Modular System for Novel Vaccines," <i>Intervirology</i> 45:212-217, S. Karger AG (2002)	
	NPL54	Levy, H.B., "Induction of Interferon <i>in Vivo</i> and <i>in Vitro</i> by Polynucleotides and Derivatives, and Preparation of Derivatives," <i>Methods Enzymol.</i> 78:242-251, Academic Press, Inc. (1981)	
	NPL55	Li, Y., <i>et al.</i> , "Vaccination Against Angiogenesis-Associated Antigens: A Novel Cancer Immunotherapy Strategy," <i>Curr. Mol. Med.</i> 3:773-779, Bentham Science Publishers Ltd. (December 2003)	
	NPL56	Luo, L., <i>et al.</i> , "Induction of V3-Specific Cytotoxic T Lymphocyte Responses by HIV gag Particles Carrying Multiple Immunodominant V3 Epitopes of gp120," <i>Virology</i> 240:316-325, Academic Press (1998)	
	NPL57	Malling, H.-J., and Taudorf, E., "Allergenicity of alum-precipitated grass pollen extracts with different RAST activity," <i>Clin. Allergy</i> 17:399-404, Blackwell Scientific Publications (1987)	
	NPL58	Martin, S.J., <i>et al.</i> , "Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses," <i>AIDS</i> 7:1315-1323, Current Science Ltd. (1993)	
	NPL59	McMichael, A.J., and Rowland-Jones, S.L., "Cellular immune responses to HIV," <i>Nature</i> 410:980-987, Macmillan Magazines Ltd. (2001)	
	NPL60	Moingeon, P., "Strategies for designing vaccines eliciting Th1 responses in humans," <i>J. Biotechnol.</i> 98:189-198, Elsevier Science B.V. (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	7	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL61	Moss, R.B., <i>et al.</i> , "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides," <i>Vaccine</i> 18:1081-1087, Elsevier Science, Ltd. (2000)	
	NPL62	Murphey-Corb, M., <i>et al.</i> , "A Formalin-Inactivated Whole SIV Vaccine Confers Protection in Macaques," <i>Science</i> 246:1293-1297, American Association for the Advancement of Science (1989)	
	NPL63	Neirynck, S., <i>et al.</i> , "A universal influenza A vaccine based on the extracellular domain of the M2 protein," <i>Nature Med.</i> 5:1157-1163, Nature America Inc. (1999)	
	NPL64	Nieland, J.D., <i>et al.</i> , "Chimeric Papillomavirus Virus-like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>J. Cell. Biochem.</i> 73:145-152, Wiley-Liss Inc. (1999)	
	NPL65	Notka, F., <i>et al.</i> , "Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies," <i>Vaccine</i> 18:291-301, Elsevier Science, Ltd. (2000)	
	NPL66	Ohashi., P.S., <i>et al.</i> , "Ablation of 'Tolerance' and Induction of Diabetes by Virus Infection in Viral Antigen Transgenic Mice," <i>Cell</i> 65:305-317, Cell Press (1991)	
	NPL67	Oxenius, A., <i>et al.</i> , "Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection," <i>Proc. Natl. Acad. Sci. USA</i> 99:13747-13752, National Academy of Sciences (2002)	
	NPL68	Oxenius, A., <i>et al.</i> , "CpG-containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines," <i>J. Virol.</i> 73:4120-4126, American Society for Microbiology (1999)	
	NPL69	Pasek, M., <i>et al.</i> , "Hepatitis B virus genes and their expression in <i>E. coli</i> ," <i>Nature</i> 282:575-579, Macmillan Journals Ltd. (1979)	
	NPL70	Pearson, W.R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," <i>Methods Enzymol.</i> 183:63-98, Academic Press, Inc. (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	8	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL71	Pedersen, N.C., <i>et al.</i> , "Isolation of a T-Lymphotropic Virus from Domestic Cats with an Immunodeficiency-Like Syndrome," <i>Science</i> 235:790-793, American Association for the Advancement of Science (1987)	
	NPL72	Pircher, H., <i>et al.</i> , "Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen," <i>Nature</i> 342:559-561, Nature Publishing Company (1989)	
	NPL73	Preikschat, P., <i>et al.</i> , "Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells," <i>J. Gen. Virol.</i> 80:1777-1788, SGM (1999)	
	NPL74	Pumpens, P., and Grens, E., "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirology</i> 44:98-114, S. Karger AG (2001)	
	NPL75	Pushko, P., <i>et al.</i> , "Analysis of RNA phage <i>φ</i> coat protein assembly by insertion, deletion and substitution mutagenesis," <i>Protein Eng</i> 6:883-891, Oxford University Press (1993)	
	NPL76	Rammensee, H., <i>et al.</i> , "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> 50:213-219, Springer-Verlag (1999)	
	NPL77	Renkvist, N., <i>et al.</i> , "A listing of human tumor antigens recognized by T cells," <i>Cancer Immunol. Immunother.</i> 50:3-15, Springer Verlag (2001)	
	NPL78	Roth, J.F., "The yeast Ty virus-like particles," <i>Yeast</i> 16:785-795, John Wiley & Sons Ltd. (2000)	
	NPL79	Rueda, P., <i>et al.</i> , "Minor Displacements in the Insertion Site Provoke Major Differences in the Induction of Antibody Responses by Chimeric Parvovirus-like Particles," <i>Virology</i> 263:89-99, Academic Press (1999)	
	NPL80	Ruedl, C., <i>et al.</i> , "Cross-presentation of virus-like particles by skinderived CD8 ⁺ dendritic cells: a dispensable role for TAP," <i>Eur. J. Immunol.</i> 32:818-825, WILEY-VCH Verlag GmbH (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	9	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL81	Salunke, D.M., <i>et al.</i> , "Self-Assembly of Purified Polyomavirus Capsid Protein VP ₁ ," <i>Cell</i> 46:895-904, Cell Press (1986)	
	NPL82	Sasnauskas, K., <i>et al.</i> , "Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles," <i>Biol. Chem.</i> 380:381-386, Walter de Gruyter (1999)	
	NPL83	Shiver, J.W., <i>et al.</i> , "Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity," <i>Nature</i> 415:331-335, Macmillan Magazines Ltd. (2002)	
	NPL84	Slepushkin, V.A., <i>et al.</i> , "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," <i>Vaccine</i> 13:1399-1402, Elsevier Science, Ltd. (1995)	
	NPL85	Smiley, B.K., and Minion, F.C., "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," <i>Gene</i> 134:33-40, Elsevier Science Publishers B.V. (1993)	
	NPL86	Sparwasser, T., <i>et al.</i> , "Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis," <i>J. Immunol.</i> 162:2368-2374, American Association of Immunologists (1999)	
	NPL87	Speiser, D.E., <i>et al.</i> , "In vivo activation of melanoma-specific CD8 ⁺ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells," <i>Eur. J. Immunol.</i> 32:731-741, WILEY-VCH Verlag GmbH (2002)	
	NPL88	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exper. Hematol.</i> 24:859-862, International Society for Experimental Hematology (1996)	
	NPL89	Storni, T., <i>et al.</i> , "Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles," <i>J Immunol.</i> 168:2880-2886, The American Association of Immunologists (2002)	
	NPL90	Stott, E.J., <i>et al.</i> , "Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine," <i>Lancet</i> 336:1538-1541, Lancet Publishing Group (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	10	of	11	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL91	Taylor, K.M., <i>et al.</i> , "Position-Dependent Processing of Peptides Presented on the Surface of Cowpea Mosaic Virus," <i>Biol. Chem.</i> 380:387-392, Walter de Gruyter (1999)	
	NPL92	Tissot, A.C., <i>et al.</i> , "Characterizing the functionality of recombinant T-cell receptors in vitro: a pMHC tetramer based approach," <i>J. Immunol. Methods</i> 236:147-165, Elsevier Science B.V. (2000)	
	NPL93	Torrence, P.F., "Preparation of a Synthetic Polynucleotide Interferon Inducer," <i>Methods Enzymol.</i> 78:326-331, Academic Press, Inc. (1981)	
	NPL94	Touze, A., <i>et al.</i> , "Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells," <i>J. Gen. Virol.</i> 82:3005-3009, SGM (2001)	
	NPL95	Turner, B.G., and Summers, M.F., "Structural Biology of HIV," <i>J. Mol. Biol.</i> 285:1-32, Academic Press (1999)	
	NPL96	Valmori, D., <i>et al.</i> , "Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues," <i>J. Immunol.</i> 160:1750-1758, American Association of Immunologists (1998)	
	NPL97	Van Schooten, W., <i>et al.</i> , "Biological properties of dendritic cells: implications to their use in the treatment of cancer," <i>Mol. Med. Today</i> 255:254-260, Elsevier Science Ltd. (1997)	
	NPL98	Vasiljeva, I., <i>et al.</i> , "Mosaic Q β coats as a new presentation model," <i>FEBS Lett.</i> 431:7-11, Federation of European Biochemical Societies (1998)	
	NPL99	Witte, L., <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy," <i>Cancer Metastasis Rev.</i> 17:155-161, Kluwer Academic Publishers (1998)	
	NPL100	Yuan, T.T.-T., <i>et al.</i> , "Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen," <i>J. Virol.</i> 73:10122-10128, American Society for Microbiology (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1615
				Examiner Name	<i>To Be Assigned</i>
				Attorney Docket Number	1700.0630000/BJD/WBC
Sheet	11	of	11		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

599067_1.DOC